Table 1.

Patient characteristics, duration of treatment, GH and IGF-1 levels at diagnosis and at the last evaluation during long-term somatostatin analogue treatment

Patient	Sex	Age at diagnosis	Duration of treatment (years)	Status of adenoma	Initial GH (ng/ml)	Final GH (ng/ml)	Initial IGF-1 (% ULN)	Final IGF-1 (% ULN)
1	F	61	12	Macro	6	0·5	284	97
2	M	61	8	Macro	6·8	0·2	286	95
3	M	51	8	Micro	6·3	0·3	341	96
4	M	56	8	Macro	2·5	0·8	445	274
5	F	54	13	Macro	7	0·5	128	82
6	F	52	5	Macro	2·5	0·8	247	247
7	M	68	3	Macro	82	9·3	749	301
8	F	38	3	Macro	2·5	4	203	206
9	F	57	4	ES	8	0·8	167	95
10	F	45	3	Macro	35	10·6	234	217
11	M	17	10	Macro	6	0·3	116	40
12	F	63	5	ES	8	0·6	263	82
13	F	68	5	Macro	20	1	424	90
14	F	41	3	Macro	75	10	278	288
15	F	45	12	Micro	3·3	0·3	197	80
16	F	65	13	Macro	8·2	1·7	–	46
17	F	75	4	Macro	4·5	3·7	417	99
18	F	71	6	Macro	5·5	2	247	100
19	M	43	5	Macro	6·5	0·7	249	42
20	M	45	18	Micro	–	2	614	161
21	M	67	9	Macro	15	2	–	59
22	M	66	12	Macro	10	2·7	–	192
23	F	21	17	Macro	28	0·3	–	54
24	F	63	10	Micro	2·5	0·3	287	83
25	M	70	3	Macro	3·6	2·7	191	193
26	F	52	8	ES	2	0·3	353	100
27	M	28	10	Macro	16·2	2·1	247	153
28	M	28	3	Micro	14·5	3·1	–	84
29	M	57	4	Macro	14	2·2	307	200
30	F	74	3	Micro	9	3·8	56	57
31	M	42	16	Micro	6·2	1	–	91
32	M	49	7	Macro	4·4	1·8	358	163
33	F	62	12	Macro	5·3	1·8	341	100
34	M	41	4	Macro	40	0·8	526	98
35	F	70	3	Macro	2·9	1·4	254	88
36	M	62	11	Micro	3·5	1	262	92
Mean ± SEM		53 ± 2·5	7·8 ± 0·7		13·5 ± 3·1	2·7 ± 0·7	302 ± 26	126 ± 12

M, male; F, female; Macro, macroadenoma; Micro, microadenoma; ES, empty sella turcica.